Spyre Therapeutics Quarterly Cash Flow Statement
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
85.69+5.79 (+7.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Spyre Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Spyre Therapeutics generated -$69.9 million of operating cash flow. That left free cash flow of -$69.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Spyre Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -36.20M | -69.00M | -62.53M | -11.18M | -36.72M | -44.77M | -56.30M | -69.03M | -38.84M | -43.86M | -63.18M | -40.11M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.51M | 12.81M | 9.81M | 9.57M | 9.38M | 8.86M | 9.22M | 13.10M | 8.70M | 13.84M | 17.27M | 4.80M |
| Change in Working Capital | -5.58M | -3.44M | -1.43M | -2.41M | -4.22M | 3.48M | -3.23M | 5.22M | -6.98M | 1.83M | -685.00K | 381.00K |
| Operating Cash Flow | -69.88M | -57.37M | -44.58M | -37.12M | -46.56M | -40.99M | -37.20M | -29.42M | -62.25M | -28.54M | -31.04M | -34.60M |
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | 0 | — |
| Investing Cash Flow | -297.90M | 56.58M | -247.41M | 25.00M | 79.00M | -61.00K | -170.54M | 42.74M | -120.52M | -104.96M | -35.27M | -97.63M |
| Financing Cash Flow | 432.60M | 12.26M | 312.81M | -4.64M | 731.00K | 125.00K | 225.60M | 12.78M | 360.00K | 172.16M | 163.61M | -12.53M |
| Net Change in Cash | 64.82M | 11.46M | 20.82M | -16.76M | 33.17M | -40.93M | 17.84M | 26.11M | -182.41M | 38.66M | 97.32M | -144.78M |
| Free Cash Flow | -69.88M | -57.37M | -44.58M | -37.12M | -46.56M | -40.99M | -37.20M | -29.42M | -62.25M | -28.54M | -31.04M | -34.60M |
This table shows 12 quarterly periods of Spyre Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SYRE's reporting calendar. What is a cash flow statement?